ProCE Banner Activity

ELEVATE-RR: Characterization of BTKi-Related AEs in Acalabrutinib vs Ibrutinib in Previously Treated CLL

Slideset Download
Conference Coverage
Event-based analyses show that acalabrutinib had a lower incidence, exposure-adjusted incidence, and exposure-adjusted time with events of CV-related toxicities (eg, afib/flutter, hypertension, and bleeding) compared with ibrutinib in this head-to-head phase III trial.

Released: December 15, 2021

Expiration: December 14, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation